By Colin Kellaher


Regeneron Pharmaceuticals has inked a deal with privately held Mammoth Biosciences to research, develop and commercialize Crispr-based gene-editing therapies targeting multiple diseases.

Regeneron on Thursday said it will make a $100 million up-front payment to Mammoth, including a $95 million equity investment in the biotechnology company.

Tarrytown, N.Y., biotechnology company Regeneron said it will pair its delivery technologies with Mammoth's proprietary Crispr-based gene-editing platform to advance in-vivo programs in multiple tissue and cell types.

Regeneron said Mammoth will be eligible to receive up to $370 million per target in development, regulatory and commercial milestone payments, along with royalties on sales of all collaboration products.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

04-25-24 0804ET